Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance
2023 · npj Precision Oncology · 100 citations
https://doi.org/10.1038/s41698-023-00380-1
M
Mick J M van Eijs
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
22
Papers
366
Citations
9
h-index
9
i10-index
Mick J M van Eijs is an academic researcher from Utrecht University. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Immunotherapy and Immune Responses & Immune Cell Function and Interaction. The author has an h-index of 9, co-authored 19 publications.
ORCID: 0000-0002-9763-6704Papers by this author
worksHematologic malignancies following immune checkpoint inhibition for solid tumors
2022 · Cancer Immunology Immunotherapy · 11 citations
https://doi.org/10.1007/s00262-022-03230-4
Tumor-infiltrating lymphocytes and immune-related adverse events in advanced melanoma
2024 · Immuno-Oncology Technology · 1 citations
https://doi.org/10.1016/j.iotech.2024.100714
In vitro T cell responses to PD-1 blockade are reduced by IFN-α but do not predict therapy response in melanoma patients
2024 · Cancer Immunology Immunotherapy · 1 citations
https://doi.org/10.1007/s00262-024-03760-z
Blood and tissue correlates of steroid non-response in checkpoint inhibition-induced immune-related adverse events
2025 · Communications Medicine · 0 citations
https://doi.org/10.1038/s43856-025-01164-3
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat